Post-Authorization Long-Term Safety Study of LUTATHERA
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuroendocrine Tumors
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
To assess the incidence and nature of potential long-term safety outcomes (follow-up period up to 7 years) in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.
To assess the incidence and nature of potential long-term safety outcomes (follow-up period up to 7 years) in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.
Tracking Information
- NCT #
- NCT03691064
- Collaborators
- Not Provided
- Investigators
- Study Director: Study Director Advanced Accelerator Applications
Get Well Soon